Sale disclosed
Brian Savage
Interim Chief Legal Officer
Ordinary Shares
- Reported value
- $174.22K
- Reported price
- $38.69 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
TEVA PHARMACEUTICAL INDUSTRIES LTD
Last 30 daysNo qualifying insider buying. Sales: $14.64M by 2 insiders.
Showing the first 6 of 20 trades on this page.
Interim Chief Legal Officer
Ordinary Shares
Interim Chief Legal Officer
Ordinary Shares
Interim Chief Legal Officer
Ordinary Shares
Director
Ordinary Shares
Chief Accounting Officer
Ordinary Shares
Chief Accounting Officer
Ordinary Shares
Director
Ordinary Shares
EVP, Business Development
Ordinary Shares
Director
Ordinary Shares
See "Remarks"
Ordinary Shares
See "Remarks"
Ordinary Shares
EVP, Global Operations
Ordinary Shares
EVP, Chief Financial Officer
Ordinary Shares
President and CEO
Ordinary Shares
EVP, Global Operations
Ordinary Shares
EVP, Business Development
Ordinary Shares
EVP, Business Development
Ordinary Shares
EVP, Chief Financial Officer
Ordinary Shares
Chief Accounting Officer
Ordinary Shares
EVP, Europe Commercial
Ordinary Shares
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| Interim Chief Legal Officer | Ordinary SharesSale3 trades | 7,342avg $38.85 / share | $285.22K | Sep 18Filed Sep 22 · 4d later | 3 filings
|
| Director | Ordinary SharesSale | 367,600$39.06 / share | $14.36M | Sep 18Filed Sep 22 · 4d later | SEC filing |
| Chief Accounting Officer | Ordinary SharesSale2 trades | 9,445avg $37.62 / share | $355.3K | Aug 21Filed Aug 25 · 4d later | 2 filings
|
| Director | Ordinary SharesSale | 415$37.25 / share | $15.46K | Aug 21Filed Aug 25 · 4d later | SEC filing |
| EVP, Business Development | Ordinary SharesSale10b5-1 | 18,600$36.57 / share | $680.29K | Aug 17Filed Aug 19 · 2d later | SEC filing |
| Director | Ordinary SharesSale | 17$34.87 / share | $592.71 | Aug 5Filed Aug 10 · 5d later | SEC filing |
| See "Remarks" | Ordinary SharesSale10b5-1 | 12,827$34.88 / share | $447.35K | Aug 3Filed Aug 5 · 2d later | SEC filing |
| See "Remarks" | Ordinary SharesSale10b5-1 | 25,578$34.88 / share | $892.05K | Aug 3Filed Aug 5 · 2d later | SEC filing |
| EVP, Global Operations | Ordinary SharesSale | 9,989$32.19 / share | $321.55K | Jun 18Filed Jun 22 · 4d later | SEC filing |
| EVP, Chief Financial Officer | Ordinary SharesSale10b5-1 | 106,563$34.10 / share | $3.63M | Jun 11Filed Jun 16 · 5d later | SEC filing |
| President and CEO | Ordinary SharesSale10b5-1 | 6,153$34.35 / share | $211.36K | Jun 5Filed Jun 8 · 3d later | SEC filing |
| EVP, Global Operations | Ordinary SharesSale10b5-1 | 16,195$32.87 / share | $532.33K | Jun 3Filed Jun 4 · 1d later | SEC filing |
| EVP, Business Development | Ordinary SharesSale10b5-12 trades | 41,658avg $35.58 / share | $1.48M | May 14Filed May 18 · 4d later | 2 filings
|
| EVP, Chief Financial Officer | Ordinary SharesSale10b5-1 | 153,251$35.61 / share | $5.46M | May 14Filed May 18 · 4d later | SEC filing |
| Chief Accounting Officer | Ordinary SharesSale | 10,679$36.00 / share | $384.44K | May 6Filed May 7 · 1d later | SEC filing |
| EVP, Europe Commercial | Ordinary SharesSale | 30,000$35.40 / share | $1.06M | May 5Filed May 7 · 2d later | SEC filing |
Showing the latest 20 of 22 trades. Show all 22 trades
Teva Pharmaceutical Industries Limited American Depositary Shares · Stock
The filing reports a purchase for the member.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.